For research and educational purposes only. Not medical advice.

Oxyntomodulin Reference

Educational, not medical advice reference for Oxyntomodulin: GLP-1, Fat Loss, Metabolic; regulatory status, evidence posture, source review, and…

Reference summary

Wynne 2005 (Diabetes) showed pre-meal subcutaneous oxyntomodulin reduced body weight by ~2.4% over 4 weeks in overweight and obese adults with reductions in energy intake of 25 +/- 5% (initial study meal) and 35 +/- 9% (final study meal). Wynne 2006 (Int J Obes) showed oxyntomodulin increased activity-related energy expenditure by ~26%. Native peptide has a very short half-life, so therapeutic development pivoted to long-acting analogs.

Regulatory and posture

Categories
GLP-1, Fat Loss, Metabolic
Aliases
OXM, Glucagon-37, Proglucagon 33-69, Endogenous GLP-1/glucagon dual agonist
Evidence posture
human - Foundational small human SQ trials exist, but native oxyntomodulin is not developed as a drug; modern dual-agonist programs use long-acting analogs instead.
Regulatory status
No FDA-approved oxyntomodulin drug label. Oxyntomodulin is an endogenous proglucagon-derived peptide secreted by L-cells of the distal gut. There is no active standalone drug program in the United States; modern long-acting GLP-1 / glucagon dual agonists (Cotadutide, Survodutide, Pemvidutide, Mazdutide) descend from this pharmacological scaffold.
Content review status
investigational verified

Selected public sources

Related tools